ArticleTranslational andrology and urology2025
Immunotherapy research for prostate cancer from 2000 to 2024: a bibliometric and visualization analysis.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical implication of immune check point inhibitors in advanced prostate cancer: insight from the KEYNOTE-991 trial.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer is one of the most prevalent malignant tumors among males, with its incidence rate increasing annually worldwide. Statistics indicate that within the American male population, prostate cancer has the highest incidence rate, whereas in China, it ranks sixth in terms of male cancer incidence. Furthermore, over 70% of Chinese patients with prostate cancer are diagnosed at locally advanced or metastatic stages. Compared with European and American countries, the survival rate for patients with advanced prostate cancer in China is significantly lower. Traditional therapies face limitations such as drug resistance and poor efficacy for advanced stage, particularly for metastatic castration-resistant prostate cancer (mCRPC), which has a 5-year survival rate below 30%. In recent years, immunotherapy has brought new hope to the treatment of prostate cancer. This study aims to systematically analyze literature in the field of prostate cancer immunotherapy using bibliometric methods, revealing the current research status, hotspots, and trends in this domain to provide references and insights for future studies. Methods: A bibliometric analysis of literature on prostate cancer immunotherapy [2000-2024] was conducted using the Web of Science Core Collection (WoSCC). Tools included VOSviewer, CiteSpace, and the R package "bibliometrix". Results: Among 2,774 articles analyzed, China and the United States dominated research output. Leading institutions included the National Cancer Institute (USA) and Memorial Sloan Kettering Cancer Center. Conclusions: Prostate cancer immunotherapy has shifted from single-agent exploration to multimodal strategies. Future priorities include overcoming "cold tumor" barriers and developing novel immune-based combination approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.